Home World News Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had... World News Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 678 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 April 6, 2022 Political Interests Are A Major Adversary in the War on Women July 6, 2021 Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... July 7, 2020 Speaking for Scotland: What our Scottish Campaigns Ambassadors want in a... August 24, 2022 Load more HOT NEWS Cancer Does Not Affect All People Equally: An Expert Q&A on... Navigating Life During and After Cancer As a Young Adult: A... Woman with Breast Cancer May Have Saved Her Twin’s Life by... EMA Recommends Extension of Indications for Durvalumab to Include Treatment of...
